8-K: Nature's Sunshine Announces Secondary Stock Offering by Major Shareholder and Concurrent Share Repurchase Plan

Nature's Sunshine Products, Inc. disclosed a secondary public offering of 2.85 million shares by Fosun Pharma USA, Inc., alongside a potential company share repurchase of up to $15 million.

Summary

• Nature's Sunshine Products, Inc. (NATR) entered into an underwriting agreement for a secondary public offering of 2,854,607 shares of its common stock.
• The shares are being sold by Fosun Pharma USA, Inc. (the Selling Stockholder) at a public offering price of $12.00 per share.
• The Company will not receive any proceeds from this secondary offering.
• Concurrently, the Company entered into a share repurchase agreement with the Selling Stockholder, allowing it to purchase up to $15.0 million worth of shares from the underwriters at the public offering price.
• The concurrent share repurchase was approved by the Company's Board of Directors and its Audit Committee.
• Any shares repurchased by the Company will be cancelled and no longer outstanding.
• The Company anticipates funding the share repurchase, if any, from cash on-hand and funds drawn from its credit facility.
• A 90-day lock-up period is in effect for the Selling Stockholder, the Company's directors, executive officers, and certain significant stockholders, restricting sales or transfers of company securities, subject to limited exceptions.

Sentiment

Score: 6

Explanation: The sentiment is moderately neutral to slightly negative. While the company's share repurchase program is a positive signal of confidence and potential share count reduction, the fact that a major shareholder is divesting a significant stake without the company receiving any proceeds from the offering could be viewed as a negative indicator by the market.

Positives

• The Company's potential share repurchase program, up to $15.0 million, indicates management confidence and could reduce the number of outstanding shares, potentially boosting earnings per share.
• Repurchased shares will be cancelled, directly reducing dilution for existing shareholders.
• The 90-day lock-up agreement for the Selling Stockholder and insiders provides a period of stability, preventing immediate further sales by these parties.

Negatives

• The Company will not receive any proceeds from the secondary offering, meaning no direct capital infusion for business operations or growth initiatives.
• A significant block of shares (2,854,607) is being sold by a major shareholder (Fosun Pharma USA, Inc.), which could be perceived by the market as a lack of long-term commitment or a negative signal.
• The Company has not agreed to purchase a minimum amount of shares in the concurrent repurchase and 'may determine to purchase fewer or no shares,' introducing uncertainty regarding the actual impact of the repurchase program.

Risks

• Forward-looking statements, including the anticipated closing of the Offering and the concurrent share repurchase, are subject to risks and uncertainties, many of which are beyond the Company's control.
• Risks include the ability of the Company and the Selling Stockholder to satisfy certain conditions to closing on a timely basis or at all.
• Other risks are described in the 'Risk Factors' section of the Company's Annual Report on Form 10-K filed March 11, 2025, and in other SEC filings (Forms 8-K and 10-Q).

Future Outlook

The document contains forward-looking statements related to the anticipated closing of the secondary offering and the concurrent share repurchase. These statements are based on management's current expectations and are subject to various risks and uncertainties that could cause actual results to differ materially.

Industry Context

NA

Corporate Governance

Related Party Transactions

• Fosun Pharma USA, Inc. is the Selling Stockholder in the secondary offering and is also a party to the Share Repurchase Agreement with Nature's Sunshine Products, Inc.

Stakeholder Impact

• **Shareholders:** The secondary offering by a major shareholder could increase the public float and potentially create selling pressure. However, the concurrent share repurchase could mitigate this by reducing the total outstanding shares, potentially benefiting remaining shareholders through increased earnings per share.
• **Fosun Pharma USA, Inc.:** This transaction allows Fosun Pharma USA, Inc. to monetize a significant portion of its investment in Nature's Sunshine Products, Inc.
• **Company:** The Company does not receive direct proceeds from the secondary offering, but the potential share repurchase could be a strategic move to optimize its capital structure and demonstrate value to investors.

Next Steps

• The secondary offering is expected to close on or about June 27, 2025, subject to customary closing conditions.
• The Company may proceed with the concurrent share repurchase of up to $15.0 million in shares from the underwriters.
• Any shares repurchased by the Company will be cancelled.

Key Dates

Recommendation

Keywords

Secondary Offering, Share Repurchase, Stock Sale, Fosun Pharma USA Inc., Nature's Sunshine Products Inc., NATR, Underwriting Agreement, Public Offering, Common Stock, Lock-up Agreement